Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

• Status: Not yet recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Drug-drug interaction study of Digoxin and AT-527 (R07496998)

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Atea Pharmaceuticals, Inc.
• Collaborator: Hoffmann-La Roche
• Treatments: Digoxin

Criteria

Inclusion Criteria:

• Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug

• Females must have a negative pregnancy test at Screening and prior to dosing

• Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2

• Willing to comply with the study requirements and to provide written informed consent

Exclusion Criteria:

• Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2

• Abuse of alcohol or drugs

• Use of other investigational drugs within 28 days of dosing

• Concomitant use of prescription medications, or systemic over-the-counter medications

• Other clinically significant medical conditions or laboratory abnormalities